Design Therapeutics, Inc. (DSGN) Stock Price & Analysis
Design Therapeutics, Inc. (DSGN) closed at USD 10.49 on Thursday, October 22, 2026, down 2.24% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 10.73; the Oct 22, 2026 session ranged USD 10.44–10.85 on volume of 270,712 shares. Market capitalization is $656.48M, with a 52-week range of USD 5.4–17.25 (NMS). Source: Nexqual, retrieved October 23, 2026 at 11:43 UTC.
Also available as compact Markdown for AI agents: nexqual.com/DSGN.md
Key facts (DSGN)
- Last four reported quarters (through Jun 30, 2026): revenue $0K, net income -$70.8M, free cash flow -$55.1M (SEC filings).
- Analysts: Buy (mean 1.75 on a 1–5 scale) (8 analysts), mean target USD 21.71 (range 20–26).
- Total return with dividends: 1Y +84.0% vs S&P 500 +14.9%; 5Y -29.0% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD -0.35, revenue estimate $0K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (DSGN)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0K | $0K | $0K |
| Operating income | -$35.8M | -$67.6M | -$78.2M | -$62.4M | -$79.5M | -$79.4M |
| Net income | -$35.5M | -$63.3M | -$66.9M | -$49.6M | -$69.8M | -$70.8M |
| EPS (diluted) | -$0.77 | -$1.14 | -$1.19 | -$0.88 | -$1.22 | — |
| Free cash flow | -$30.9M | -$52.2M | -$58.8M | -$43.4M | -$54.6M | -$55.1M |
| Cash + short-term investments | $384M | $330M | $282M | $246M | $220M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (DSGN)
P/B 3.3x · FCF yield -8.40% · Earnings yield -10.78%
Analysts (DSGN)
Consensus Buy (mean 1.75 on a 1–5 scale), 8 analysts; mean target USD 21.71 (low 20, high 26).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-02 | Wells Fargo | Initiated | Overweight | $26 |
Total return (dividends reinvested) (DSGN)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +84.0% | -29.0% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +84.4% | -6.6% |
| Volatility (annualized) | 74.0% | 97.5% |
| Max drawdown | -39.0% (Aug 2026→Oct 2026) | -91.9% (Aug 2022→Nov 2023) |
DSGN suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Competitor | Eli Lilly (LLY) | “We will also compete more generally with other companies developing alternative scientific and technological approaches to modulate individual genes, including other companies working to develop nuclease-based gene editing technologies, such as Beam Therapeutics, CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Precision BioSciences, Rocket Pharmaceuticals, Sangamo Biosciences and Verve Therapeutics (a…” |
Quoted from the company's 10-K filed Mar 9, 2026.
DSGN company outlook (results filed Aug 3, 2026)
- “In addition, modifications include specifying endogenous blood FXN protein percent change from baseline as the primary efficacy endpoint and exploring a dose level above 1 mpk. • Next Steps and Expected Milestones: Design expects to provide an update on its registrational plans in the fourth quarter of 2026, with data following 12 weeks of treatment expected in the first quarter of 2027.”
- “Design anticipates reporting data from this study in 2027. • Fuchs Endothelial Corneal Dystrophy (FECD): A Phase 2 biomarker trial of DT-168 is ongoing to evaluate safety, tolerability and corneal endothelium biomarkers in FECD patients who are scheduled for corneal transplant surgery.”
- “Data is now expected in 2027 due to a delay in the anticipated supply of DT-168 blow-fill-seal eye droppers. • Huntington's disease (HD): Design continues to advance preclinical characterization of several candidate molecules for its Huntington's disease program.”
Quoted word-for-word from the SEC 8-K results press release.
DSGN analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.35 | $-0.36 | -3.4% | $0 | 8 |
| Next quarter (ends Dec 2026) | $-0.39 | $-0.37 | +5.5% | $0 | 8 |
| Current fiscal year (ends Dec 2026) | $-1.35 | $-1.36 | -0.9% | $0 | 8 |
| Next fiscal year (ends Dec 2027) | $-1.62 | $-1.64 | -1.0% | $0 | 8 |
DSGN options: expected move
Options price a move of about ±33.1% (±$3.48) by Nov 20, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±7.2% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 143.7% | ±33.1% |
| Dec 18, 2026 | 56 | 93.9% | ±32.9% |
| Jan 15, 2027 | 84 | 89.0% | ±49.6% |
| Apr 16, 2027 | 175 | 84.3% | ±47.7% |
30-day implied volatility 93% vs 68.1% realized over the last 30 trading days. Put/call ratio (volume) —. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 11:43 UTC)
| Price | USD 10.49 |
|---|---|
| Change | ▼ 2.24% (down) |
| Previous Close | USD 10.73 |
| Open | USD 10.58 |
| Day Range | USD 10.44 – 10.85 |
| 52-Week Range | USD 5.4 – 17.25 |
| Volume | 270,712 shares |
| Market Cap | $656.48M |
| Exchange | NMS |
Technical Analysis (DSGN)
Nexqual's technical model rates DSGN "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 11:43 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 34.75 (neutral) |
| vs SMA50 | Below (USD 13.2) |
| MACD | -0.73 (negative) |
Analyst Ratings (DSGN)
Wall Street analysts rate DSGN "Buy" based on 8 analysts, with a mean price target of USD 21.71 (range USD 20–26), per Nexqual as of October 23, 2026 at 11:43 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 21.71 |
| High Target | USD 26 |
| Low Target | USD 20 |
| Buy / Hold / Sell | 8 / 0 / 0 |
Earnings (DSGN)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.35 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.32 vs est -0.34 ▲ beat |
| 2026-03-31 | USD -0.29 vs est -0.33 ▲ beat |
| 2025-12-31 | USD -0.27 vs est -0.35 ▲ beat |
| 2025-09-30 | USD -0.3 vs est -0.34 ▲ beat |
Source: Nexqual, October 23, 2026 at 11:43 UTC.
Financials & Fundamentals (DSGN)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -34.13% |
| Debt / Equity | 0.01 |
| Current Ratio | 18.86 |
| Total Cash | $207.40M |
| Total Debt | $2.66M |
Source: Nexqual, October 23, 2026 at 11:43 UTC.
Financial Health Score (DSGN)
Nexqual rates Design Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 11:43 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $207M cash vs $3M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$54M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -34%, ROA -22.5% |
Ownership (DSGN)
| Insider Ownership | +31.87% |
|---|---|
| Institutional Ownership | +78.70% |
| Shares Outstanding | 62.58M |
| Float | 36.19M |
| Short % of Float | +14.00% |
Source: Nexqual, October 23, 2026 at 11:43 UTC.
Leadership (DSGN)
Design Therapeutics, Inc. is led by Pratik Shah, Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson, per Nexqual as of October 23, 2026 at 11:43 UTC.
| Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson | Pratik Shah |
|---|---|
| Chief Operating Officer | Sean Jeffries |
| Chief Technology Officer | Doane Chilcoat |
| Chief Scientific Officer | Tadimeti S. Rao |
Major Backers & Investors (DSGN)
Notable institutional backers of Design Therapeutics, Inc. include SR One Capital Management, LP, Logos Global Management LP, Baker Bros. Advisors, LP, according to Nexqual as of October 23, 2026 at 11:43 UTC.
Active Investors
| Investor | Stake |
|---|---|
| SR One Capital Management, LP | 10.43% |
| Logos Global Management LP | 4.79% |
| Baker Bros. Advisors, LP | 4.28% |
| Driehaus Capital Management, LLC | 4.25% |
| Point72 Asset Management, L.P. | 3.78% |
| Trails Edge Capital Partners, LP | 3.2% |
| Frazier Life Sciences Management, L.P. | 2.89% |
| Vivo Capital, LLC | 2.58% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 4.25% |
| Vanguard Group | 2.51% |
Source: Nexqual, October 23, 2026 at 11:43 UTC.
From Design Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-09)
Key Strengths & Strategy (as disclosed to the SEC)
- We have developed a proprietary framework that combines our understanding of medicinal chemistry and structure-activity relationships that allow us to design DNA-targeting moieties that are connected via a linker to ligand moieties that engage and modulate the transcriptional machinery.
- We utilize our proprietary GeneTAC® platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
- We developed DT-216P2 using a proprietary and novel excipient.
- Because GeneTAC® molecules are designed to be a novel class of disease-modifying small molecule therapeutic candidates, we have selected disease programs where we believe the underlying cause is amenable to intervention using our technology and prioritized our development efforts where we believe there is a clear and efficient path to advance these candidates through clinical development, with the goal of providing a disease-modifying therapy for patients.
Legal & Regulatory Risks (Item 1A, quoted)
- Our business operations and current and future relationships with investigators, health care professionals, consultants, third-party payors and customers are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, transparency laws and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.
- We expect that the healthcare reform measures that have been adopted, and that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product and could seriously harm our future revenues.
- Risks Related to Our Intellectual Property
- The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 307.82 | ▼ 2.21% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 90.9 | ▲ 2.57% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.14 | ▼ 3.28% |
| PRAX | Praxis Precision Medicines, Inc | USD 258.92 | ▲ 0.96% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.91 | ▼ 0.81% |
| ABVX | Abivax SA | USD 90.23 | ▼ 3.49% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 11:43 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt